

## Publikationen PD Dr. R. Seggewiss-Bernhardt

### A Originalpublikationen

#### Nach Habilitation:

Nr.	Publikation	Impact factor
1.	N. Giesen, E. Busch, E. Schalk, G. Beutel, M. Ruethrich, M. Hentrich, B. Hertenstein, H. H. Hirsch, M. Karthaus, Y. Khodamoradi, P. Koehler, W. Krüger, M. Koldehoff, R. Krause, S. C. Mellinghoff, O. Penack, M. Sandherr, <b>R. Seggewiss-Bernhardt</b> , K. Spiekermann, R. Sprute, J. Stemler, J. Vehreschild, F. Weissinger, B. Woermann, H.-H. Wolf, O. A. Cornely, C. Rieger, M. von Lilienfeld-Toal. AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variant. Eur J Cancer. 2022 Dec 10;181:102-118. doi: 10.1016/j.ejca.2022.11.030. Online ahead of print.	9,162
2.	L. Müller-Jensen, S. Zierold, J.M. Versluis, W. Boehmerle, P. Huehnchen, M. Endres, R. Mohr, A. Compter, C. U. Blank, T. Hagenacker, F. Meier, L. Reinhardt, A. Gesierich, M. Salzmann, J.C., S.Ugurel, L. Zimmer, P. Banks, L. Spain, J.A. Soon, T. Enokida, M. Tahara, K. C. Kähler, <b>R. Seggewiss-Bernhardt</b> , C. Harvey, G. V. Long, F. Schöberl, L. von Baumgarten, T. Hundsberger, M. Schlaak, L. E. French, S. Knauss, L. M. Heinzerling. Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis. Data Brief. 2022 Sep 30;45:108649. doi: 10.1016/j.dib.2022.108649. eCollection 2022 Dec.	1,133
3.	M. Hanoun, L. Ruhnke, M. Kramer, C. Hanoun, K. Schäfer-Eckart, B. Steffen, T. Sauer, S. W Krause, C. Schliemann, J.-H. Mikesch, M. Kaufmann, M. Hänel, E. Jost, T. H. Brümmendorf, L. Fransecky, S. Kraus, H. Einsele, D. Niemann, A. Neubauer, J. Kullmer, <b>R. Seggewiss-Bernhardt</b> , M. Görner, G. Held, U. Kaiser, S. Scholl, A. Hochhaus, H. C. Reinhardt, U. Platzbecker, C. D Baldus, C. Müller-Tidow, M. Bornhäuser, H. Serve, C. Röllig; Study Alliance Leukemia (SAL). Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry. J Cancer Res Clin Oncol. 2022 Sep 28. doi: 10.1007/s00432-022-04356-9.	4,553
4.	S. Kayser, D. Martínez-Cuadrón, M. Hanoun, F. Stölzel, C. Gil, H. C. Reinhardt, E. Aguiar, K. Schäfer-Eckart, J. M. Bergua Burgues, B. Steffen, T. Bernal, S. W. Krause, R. Riaza, C. Schliemann, J. Cervera, M. Kaufmann, L. Torres-Miñana, M. Hänel, E. Acuña-Cruz, E. Jost, J. L. Algarra, M. Crysandt, L. Fransecky, J. Cornago Navascues, S. Kraus, J. Martinez-Lopez, H. Einsele, D. Niemann, A. Neubauer, <b>R. Seggewiss-Bernhardt</b> , S. Scholl, S. A. Klein, C. Schmid, M. Schaich, M. Schmidt-Hieber, S. Zukunft, A. D. Ho, U. Platzbecker, C. D. Baldus, C. Müller-Tidow, C. Thiede, M. Bornhäuser, H. Serve, M. Levis, P. Montesinos, C. Röllig, and R. F. Schlenk. Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4. Haematologica. 2022 Jun 9. doi: 10.3324/haematol.2022.281137.	9,941

5.	L. Mueller-Jensen, S. Zierold, J. M. Versluis, W. Boehmerle, P. Huehnchen, M. Endres, R. Mohr, A. Compter, C. U. Blank, T. Hagenacker, F. Meier, L. Reinhardt, A. Gesierich, M. Salzmann, J. C. Hassel, S. Ugurel, L. Zimmer, P. Banks, L. Spain, J. A. Soon, T. Enokida, M. Tahara, K. C. Kähler, <b>R. Seggewiss-Bernhardt</b> , C. Harvey, G. V. Long, F. Schoeberl, L. von Baumgarten, T. Hundsberger, M. Schlaak, L. E. French, S. Knauss, L. M. Heinzerling. Characteristics of Immune Checkpoint Inhibitor-induced Encephalitis and Comparison with HSV-1 and Anti-LGI1 Encephalitis – A Retrospective Multicenter Study. <i>European Journal of Cancer</i> , 175 (2022) 224-235.	9,162
6.	C. Schubart, R. Stöhr, L. Tögel, F. Fuchs, H. Sirbu, G. Seitz, <b>R. Seggewiss-Bernhardt</b> , R. Leistner, W. Sterlacci, M. Vieth, C. Seidl, M. Mugler, M. Kapp, W. Hohenforst-Schmidt, A. Hartmann, F. Haller, R. Erber. MET amplification in non-small cell lung cancer (NSCLC) – A consecutive evaluation using next generation sequencing (NGS) in a real world setting, <i>Cancers (Basel)</i> . 2021 Oct 7;13(19):5023. doi: 10.3390/cancers13195023.	6,102
7.	A. Kiani, R. Rösch, C. M. Wendtner, F. Kullmann, T. Kubin, J. Lanznaster, M. Wilhelm, M. Schaich, C. Müller-Naendrup, G. Illerhaus, F. Hartmann, H. Hebart, <b>R. Seggewiss-Bernhardt</b> , M. Bentz, E. Späth-Schwalbe, P. Reimer, U. Kaiser, M. Kapp, U. Graeven, J.-M. Chemnitz, J. Baesecke, H. Lambertz, R. Naumann. <i>Cancer Med.</i> 2021 Jul;10(13):4424-4436. doi: 10.1002/cam4.4023.	4,452
8.	D. Kajaia, B. Hager, S. Kliebisch, K. Weingärtner, <b>R. Seggewiss-Bernhardt</b> , V. Zugor. Robot-assisted laparoscopic bladder diverticulum resection (RABDR). <i>Aktuelle Urol.</i> 2021 May 11. doi: 10.1055/a-1327-5509.	0,21
9.	D. Kajaia, B. Hager, S. Kliebisch, K. Weingärtner, G. Seitz, U. von Streitberg, <b>R. Seggewiss-Bernhardt</b> , V. Zugor. Ein seltener Fall eines renalen ektopen Schilddrüsengewebes, [A rare case of renal ectopic thyroid tissue]. <i>Aktuelle Urol.</i> 2021 Feb;52(1):64-66. doi: 10.1055/a-1182-1961.	0,21
10.	H.-D. Hummel, P. Kufer, C. Grüllich, <b>R. Seggewiss-Bernhardt</b> , B. Deschler-Baier, M. Chatterjee, M. -E. Goebeler, K. Miller, M. De Santis, W. Loidl, C. Dittrich A. Buck, C. Lapa, A. Thurner, S. Wittmer-Rump, G. Koca, O. Boix, W.-D. Döcke, R. Finner, H. Kusi, A. Ajavon-Hartmann, S. Stienen, C. M. Sayehli, B. Polat, R. C. Bargou. Pasotuxizumab (AMG 212/BAY 2010112), a PSMA-Directed BiTE® (Bispecific T-Cell Engager) Immune Therapy for Castration-Resistant Prostate Cancer: Results of an Open-Label, Phase 1, Dose-Escalation Study, <i>Immunotherapy.</i> 2021 Feb;13(2):125-141. doi: 10.2217/imt-2020-0256.	7,397
11.	A. J. Coles, L. Azzopardi, O. Kousin-Ezewu, H. K. Mulla, S. A. J. Thompson, L. Jarvis, J. Davies, S. Howlett, D. Rainbow, J. Babar, T. J. Sadler, W. L. Brown, E. Needham, K. May, Z. G. Georgieva, A. E. Handel, S. Maio, M. Deadman, I. Rota, G. Hollander, S. Dawson, D. Jayne, <b>R. Seggewiss-Bernhardt</b> , D. C. Douek, J. D. Isaacs and J.L. Jones. Keratinocyte growth factor impairs human thymic recovery from lymphopenia. <i>JCI Insight.</i> 2019 May 7;5. pii: 125377. doi: 10.1172/jci.insight.125377.	6,205
12.	D. Juric, F. Janku, J. Rodón, H. A. Burris, I. A. Mayer, M. Schuler, <b>R. Seggewiss-Bernhardt</b> , M. Gil-Martin, M. R. Middleton, J. Baselga, D. Bootle, D.	22,4

	Demanse, L. Blumenstein, K. Schumacher, A. Huang, C. Quadt, H. S. Rugo. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial. <i>JAMA Oncol.</i> 2019 Feb 1;5(2):e184475. doi: 10.1001/jamaoncol.2018.4475.	
13.	S. Michels, C. Heydt, B. van Veggel, B. Deschler-Baier, N. Pardo, K. Monkhorst, V. Rüsseler, J. Stratmann, F. Griesinger, S. Steinhauser, A. Kostenko, J. Diebold, J. Fassunke, R. Fischer, W. Engel-Riedel, O. Gautschi, E. Geissinger, S. Haneder, M. A. Ihle, H.-G. Kopp, A. J. de Langen, A. Martinez-Marti, L. Nogova <sup>1</sup> , T. Persigehl, D. Plenker, M. Puesken, E. Rodermann, A. Rosenwald, A. H. Scheel, M. Scheffler, W. Spengler, <b>R. Seggewiss-Bernhardt</b> , M. Sebastian, B. Vrugt, M. Hellmich, R. Thomas, M. L. Sos, L. C. Heukamp, E. Felip, S. Merkelbach-Bruse, E. F. Smit, R. Büttner, J. Wolf. Genomic profiling identifies outcome-relevant mechanisms of innate and acquired resistance to third-generation EGFR tyrosine kinase inhibitor therapy in lung cancer. <i>JCO Precis Oncol.</i> 2019 Mar 27;3:PO.18.00210. doi: 10.1200/PO.18.00210. eCollection 2019. PMID: 32914023	3,06
14.	M. Kebenko, M. E. Goebeler, M. Wolf, A. Hasenburg, <b>R. Seggewiss-Bernhardt</b> , B. Ritter, B. Rautenberg, D. Atanackovic, A. Kratzer, J. B. Rottman, M. Friedrich, E. Vieser, S. Elm, I. Patzak, D. Wessiepe, S. Stienen, W. Fiedler. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE <sup>®</sup> ) antibody construct, in patients with refractory solid tumors. <i>Oncoimmunology.</i> 2018 Apr 18;7(8):e1450710. doi: 10.1080/2162402X.2018.1450710.	4,84
15.	J. Lohmeyer, T. Nerreter, J. Dotterweich, H. Einsele, <b>R. Seggewiss-Bernhardt</b> . Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose and time-dependent manner. <i>Clin Exp Immunol.</i> 2018 Jul;193(1):64-72. doi: 10.1111/cei.13128.	3,827
16.	D. Juric, J. Rodon, J. Tabernero, F. Janku, H. A. Burris, J. H. M. Schellens, M. R. Middleton, J. Berlin, M. Schuler, M. Gil-Martin, H. Rugo, <b>R. Seggewiss-Bernhardt</b> , A. Huang, D. Bootle, D. Demanse, L. Blumenstein, C. Coughlin, C. Quadt, J. Baselga. PI3K $\alpha$ -selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: Results from the first-in-human study. <i>J Clin Oncol.</i> 2018 May 1;36(13):1291-1299. doi: 10.1200/JCO.2017.72.7107.	28,245
17.	J. P. Veluchamy, M. Delso-Vallejo, N. Kok, F. Bohme, <b>R. Seggewiss-Bernhardt</b> , H. J. van der Vliet, T. D. de Gruijl, V. Huppert, J. Spanholtz. Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function. <i>Sci Rep.</i> 2017 Mar 10;7:43873.	4,61
18.	T. Nerreter, S. Zeiß, T. Herrmann, H. Einsele, <b>R. Seggewiss-Bernhardt</b> . Robust 8-color flow cytometry panel reveals enhanced effector function of NKG2C <sup>+</sup> CD57 <sup>+</sup> Fc $\epsilon$ R $\gamma$ <sup>-</sup> NK cells in CMV seropositive human blood donors. <i>Immunobiology.</i> 2017 May;222(5):719-725.	2,873
19.	S. Hausmann, E. Brandt, C. Köchel, H. Einsele, R. C. Bargou, <b>R. Seggewiss-Bernhardt*</b> , T. Stühmer*. Loss of Serum and Glucocorticoid-Regulated Kinase 3 (SGK3) Does Not Affect Proliferation and Survival of Multiple	3,234

	Myeloma Cell Lines. PLoS One. 2015 Apr 2;10(4):e0122689. <i>*contributed equally to the paper</i>	
20.	<b>R. Seggewiss-Bernhardt</b> , R. C. Bargou, Y. T. Goh, A.K. Stewart, A. Spencer, A. Alegre, J. Bladé, O. G. Ottmann, C. Fernandez-Ibarra, H. Lu, S. Pain, M. Akimov, S. P. Iyer. Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer. 2015 Jul 1;121(13):2185-92.	5,649
21.	T. Nerreter, C. Köchel, D. Jesper, I. Eichelbrönnner, E. Putz, H. Einsele, <b>R. Seggewiss-Bernhardt</b> . Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 and Siglec-3. Exp Hematol. 2014 Sep;42(9):773-82.e1-3.	2,53
22.	I. Jungkunz-Stier, M. Zekl, T. Stühmer, H. Einsele, <b>R. Seggewiss-Bernhardt</b> . Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells. Leuk Lymphoma. 2014 Jan;55(1):168-76.	2,891
23.	T. Nerreter, E. Distler, C. Köchel, H. Einsele, W. Herr, <b>R. Seggewiss-Bernhardt</b> . Combining dasatinib with dexamethasone longterm leads to maintenance of anti-viral and anti-leukemia specific cytotoxic T cell responses in vitro. Exp Hematol 2013, Jul;41(7):604-614.e4.	2,806
24.	A. Kreutzman, T. Jaatinen, D. Greco, E. Vakkila, J. Richter, M. Ekblom, H. Hjort-Hansen, L. Stenke, T. Melo, R. Paquette, <b>R. Seggewiss-Bernhardt</b> , A. Guerci-Bresler, A. Talbot, J. M. Cayuela, F. Mahon, K. Porkka, J. Lipton, J. Partanen, P. Rousselot, S. Mustjoki. Killer-cell immunoglobulin-like receptor (KIR) gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia. Exp Hematol, 2012 Nov;40(11):906-913.e1.	2,907
25.	N. Hassold, K. Seystahl, K. Kempf, D. Urlaub, M. Zekl, C. Watzl, J. Wischhusen, H. Einsele, <b>R. Seggewiss-Bernhardt</b> . Enhancement of major natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib. Int J Cancer. 2012 Sep 15;131(6):E916-27.	2,854
26.	A. Kreutzman, K. Ladell, C. Koechel, E. Gostick, M. Ekblom, L. Stenke, T. Melo, H. Einsele, K. Porkka, D. A. Price, S. Mustjoki and <b>R. Seggewiss</b> . Expansion of highly differentiated CD8 <sup>+</sup> T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia. 2011 Oct;25(10):1587-97.	9,561

**Vor Habilitation:**

Nr.	Publikation	Impact factor
1.	A. Kreutzman, V. Juvonen, V. Kairisto, M. Ekblom, L. Stenke, <b>R. Seggewiss</b> , K. Porkka, S. Mustjoki. Mono/oligoclonal T- and NK-cells are common in chronic	10,105

	myeloid leukemia patients at diagnosis and expand during successful dasatinib therapy. <i>Blood</i> . 2010 Aug 5;116(5):772-82.	
2.	T. Stühmer, M. Chatterjee, E. Grella, <b>R. Seggewiss</b> , S. Müller, J. Schoepfer, C. Garcia-Echeverria, C. Quadt, M. R. Jensen, H. Einsele and R. C. Bargou. Anti-myeloma activity of NVP-BEP800: a novel 2-aminothienopyrimidine Hsp90 inhibitor. <i>Br J Haematol</i> . 2009;147(3):319-27.	4,907
3.	A. Lissina, K. Ladell, A. Skowera, M. Clement, E. Edwards, <b>R. Seggewiss</b> , H. van den Berg, E. Gostick, K. Gallagher, E. Jones, J. J. Melenhorst, A. J. Godkin, M. Peakman, D. A. Price, A. K. Sewell and L. Wooldridge. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. <i>J Immunol Methods</i> 2009;340(1):11-24.	2,663
4.	R. Weichsel, C. Dix, L. Wooldridge, M. Clement, A. Fenton-May, A. K. Sewell, J. Zezula, E. Greiner, E. Gostick, D. A. Price, H. Einsele, <b>R. Seggewiss</b> . Profound inhibition of antigen-specific T cell effector functions by dasatinib. <i>Clin Cancer Res</i> . 2008;14(8):2484-91.	7,094
5.	C. Leder, S. Ortler, <b>R. Seggewiss</b> , H. Einsele, H. Wiendl. Modulation of T effector function by imatinib at the level of cytokine secretion. <i>Exp Hematol</i> . 2007;35:1266-71.	3,64
6.	B. E. Shepherd, H.-P. Kiem, P. M. Lansdorp, G. Aubert, C. E. Dunbar, A. LaRoche, <b>R. Seggewiss</b> , P. Guttorp, J. L. Abkowitz. Hematopoietic Stem Cell Behavior in Non-human Primates. <i>Blood</i> 2007;110:1806-13.	9,630
7.	<b>R. Seggewiss*</b> , K. Loré*, F. J. Guenaga, S. Pittaluga, J. Mattapallil, C. K. Chow, D. Ambrozak, R. T. Bailer, R. A. Koup, R. E. Donahue, C. E. Dunbar, D. C. Douek. Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques, *first co-authors, <i>Blood</i> 2007;110: 441-49.	9,630
8.	K. Loré*, <b>R. Seggewiss*</b> , F. J. Guenaga, S. Pittaluga, R.E. Donahue, A. Krouse, M.E. Metzger, R.A. Koup, C. Reilly, D.C. Douek and C.E. Dunbar. In vitro culture during retroviral transduction improves thymic repopulation and output after TBI and autologous PBPC transplantation in rhesus macaques, *first co-authors, <i>Stem Cells</i> 2006;24:1539-48.	8,056
9.	<b>R. Seggewiss</b> , S. Pittaluga, F. J. Guenaga, C. Ferguson, I. H. Pilz, R. L. Adler, B. Ryu, B. P. Sorrentino, R. E. Donahue, C. von Kalle, A. W. Nienhuis, C. E. Dunbar. Acute myeloid leukemia associated with retroviral gene transfer to hematopoietic progenitor cells of a rhesus macaque. <i>Blood</i> 2006;107:3865-67.	9,470
10.	P. F. Fogarty, <b>R. Seggewiss</b> , D. J. McCloskey, C. A. Boss, C. E. Dunbar, M. E. Rick. Anti-interleukin-2 receptor treatment of corticosteroid refractory autoimmune thrombocytopenia treatment purpura. <i>Haematologica</i> 2006;91:277-78.	5,032
11.	<b>R. Seggewiss</b> , K. Lore, E. Greiner, M. K. Magnusson, D. A. Price, D. C. Douek, C. E. Dunbar, A. Wiestner. Imatinib inhibits T-cell receptor mediated T-cell	9,694

	proliferation and activation in a dose-dependent manner. Blood 2005;105:2473-79.	
12.	K. Kuramoto, D. Follman, P. Hematti, S. Sellers, M. O. Laukkanen, <b>R. Seggewiss</b> , M. E. Metzger, A. Krouse, R. E. Donahue, C. von Kalle, C. E. Dunbar. The impact of low-dose busulfan on clonal dynamics in non-human primates. Blood 2004;104:1273-80.	9,560
13.	<b>R. Seggewiss</b> , A. D. Ho, A. Kraemer. Remarkable response to rituximab in a patient with atypical CD20++ B-cell chronic lymphocytic leukemia of the bone marrow leading to severe pancytopenia. Ann. Hematol. 2004;83:316-18.	1,663
14.	<b>R. Seggewiss</b> , E. C. Buss, D. Herrmann, H. Goldschmidt, A. D. Ho, S. Fruehauf. Kinetics of peripheral blood stem cell mobilization following G-CSF-supported chemotherapy. Stem cells 2003;21:568-74.	5,661
15.	<b>R. Seggewiss</b> , T. Hess, C. Fiehn. A family with a variant form of primary hypertrophic osteoarthropathy restricted to the lower extremities, Joint Bone Spine 2003;70:230-33.	1,193
16.	M. Goerner, <b>R. Seggewiss</b> , T. Schlenker, W. Stremmel, A. D. Ho. A Case of severe refractory thrombotic thrombocytopenic purpura responding to treatment with 13-cis retinoic acid. Br J Haematol. 2002;117:249-51.	3,356
17.	S. Fruehauf, K. Srbic, <b>R. Seggewiss</b> , J. Topaly, A. D. Ho. Functional characterization of podia formation in normal and malignant hematopoietic cells, J Leukoc Biol. 2002;71: 425-32.	4,292
18.	C. Kneitz, M. Goller, <b>R. Seggewiss</b> , A. Yaman, E. Serfling, H. P. Tony. Stat-6 and the regulation of CD23 expression in B-chronic lymphocytic leukaemia. Leuk. Res. 2000 Apr; 24(4): 331-37.	1.479

## B Reviews/Kommentare

### Vor Habilitation:

Nr.	Publikation	Impact factor
1.	<b>R. Seggewiss</b> , H. Einsele. Immune reconstitution post allogeneic hematopoietic stem cell transplantation and implications for immunomodulatory treatments: an update. Blood 2010;115(19):3861-8.	10,105
2.	<b>R. Seggewiss</b> , D. A. Price, M. A. Purbhoo. Immunomodulatory Effects of Imatinib and Second Generation Tyrosine Kinase Inhibitors on T Cells and Dendritic Cells: an update. Cytotherapy 2008;10(6):633-41.	3,755
3.	<b>R. Seggewiss</b> and H. Einsele. Hematopoietic growth factors (including KGF) in allogeneic and autologous stem cell transplantation. Semin Hem 2007;44:203-11.	3,733

4.	<b>R. Seggewiss</b> and C. E. Dunbar. A new direction for gene therapy: intrathymic T cell specific lentiviral gene transfer. Commentary, JCI 2005, 15:2064-67.	13,983
5.	<b>R. Seggewiss</b> and C. E. Dunbar. Old before its time: Age related thymic dysfunction may preclude efficacy of gene therapy in older SCID-X1 patients. Commentary, Blood 2005, 105: 4160-61.	9,694

### **C Buchkapitel**

#### **Vor Habilitation:**

1.	<b>R. Seggewiss</b> , C. E. Dunbar, D. Orlic. "Hematopoietic stem cell mobilization and homing" in "Handbook of Stem Cells", Developmental Editor: Judy Meyer, Elsevier, San Diego, USA, Aug 2004.
----	--

Bamberg, den 31.03.23